For instance, Lee and Ahn found that AAV2 modified with a streptavidin-biotin complex linked to an anti-EpCAM antibody exhibited significant efficacy in targeting EpCAM-positive ovarian cancer cells [21]. Here, EPCAM is linked to ovarian carcinoma.